• E-mail page
• Print page
• Text size   

AstraZeneca has created a variety of online tools to help engage at-risk patients in the treatment of hypercholesterolemia and mixed dyslipidemia. Click where you see "Send this link to a patient" and enter your patient's e-mail address, and a link will be sent to your patient's inbox. To order printed patient education materials from AstraZeneca or to download, customize, and print materials to give directly to patients, please visit AZOnDemand™.

Cholesterol Roadmap

By answering a series of health-related questions, your at-risk patients will have the opportunity to create a roadmap that helps determine their cholesterol goals, or "destination."

Meal Planner

The Meal Planner allows your at-risk patients to work with you to create a 7-day customizable menu, printer-friendly recipe cards, and a shopping list.

Diet and Exercise Diary

Keeping a record of diet and exercise can be a powerful motivator to stay on track.¹

Tips on Taking Your Medicines

This list of tips can help at-risk patients with multiple prescriptions stay on top of their regimen.

Atherosclerosis Visual Demonstration Animation

This animation visually demonstrates atherosclerosis, to help you help your at-risk patients better understand the condition.

Learn more about the patient support programs that AstraZeneca is using to help educate at-risk patients considering CRESTOR^® (rosuvastatin calcium) — and help patients who are taking CRESTOR stick to their cholesterol management programs.

• CRESTOR is indicated^# as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not indicated to reduce cardiovascular morbidity and mortality

Important safety information about CRESTOR

• CRESTOR is contraindicated^# in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose
• It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^‡‡